Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations
Author: Khoury, H.
Guilhot, F.
Hughes, T.
Kim, D.
Cortes, J.
Citation: Cancer, 2009; 115(7):1381-1394
Publisher: John Wiley & Sons Inc
Issue Date: 2009
ISSN: 0008-543X
Statement of
Hanna Jean Khoury, François Guilhot, Timothy P. Hughes, Dong-Wook Kim and Jorge E. Cortes
Abstract: Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.
Keywords: dasatinib; chronic myeloid leukemia; side effects; imatinib
Rights: Copyright © 2009 American Cancer Society
RMID: 0020090387
DOI: 10.1002/cncr.24155
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.